

PRODUCTS FOR OUTLICENSING

Products	Indication	Innovator Company	Innovator Brand	Strength & Dosage	BE Status	Dossier Status
Vonoprazan Tablets	Acid-related gastrointestinal disorders	Takeda	<i>Voquezna</i>	10 mg & 20 mg	Available	Available
Finerenone Tablets	Chronic kidney disease	Bayer	<i>Kerendia</i>	10 mg & 20 mg	Available	Available
Linagliptin Tablets	DPP 4 inhibitor, Type 2 diabetes mellitus	Boehringer Ingelheim & Eli Lilly	<i>Tradjenta, Trajenta</i>	5 mg	Available	Available
Apixaban Tablets	Prevention of stroke in atrial fibrillation; treatment/prevention of DVT and PE	Bristol Myers Squibb & Pfizer	<i>Eliquis</i>	2.5 mg & 5 mg	Available	Available
Eltrombopag Tablets	Immune Thrombocytopenia (ITP) & certain cases of aplastic anemia	Novartis	<i>Revolade</i>	12.5 mg, 25 mg & 50 mg	Available	Available
Vortioxetine Tablets	Major depressive disorder in adults	Takeda	<i>Brintellix</i>	5 mg, 10 mg, 15 mg & 20 mg	Available	Available
Mirabegron Tablets	Overactive bladder with urgency, frequency, & urge urinary incontinence	Astellas Pharma	<i>Myrbetriq</i>	25 mg & 50 mg	Available	Available
Edoxaban Tablets	Prevention of stroke in atrial fibrillation; treatment/prevention of DVT and PE	Daiichi Sankyo Co	<i>Savaysa</i>	15 mg, 30 mg & 60 mg	Available	Available
Mirabegron+ solifenacin Tablets	Overactive bladder, particularly urgency, frequency, & urge urinary incontinence	Astellas Pharma	<i>Myrbetriq</i>	25 mg+5 mg & 50 mg+5 mg	Available	Available
Macitentan Tablets	Pulmonary arterial hypertension (PAH); helps slow disease progression	Johnson & Johnson	<i>Opsumit</i>	10 mg	Available	Available
Esomeprazole Gastro-Resistant Tablets	GERD, erosive esophagitis, peptic ulcer disease, H. pylori eradication, NSAID-associated ulcer prevention	AstraZeneca	<i>Nexium®</i>	20 & 40 mg	Available	Available
Vildagliptin/ Metformin HCl film-coated Tablets	Type 2 Diabetes Mellitus	Novartis	<i>Eucreas® / Galvus Met®</i>	50/500 mg, 50/850 mg, 50/1000 mg	Available	Available
Sitagliptin/ Metformin HCl film-coated Tablets	Type 2 Diabetes Mellitus	Merck & Co. (MSD)	<i>Janumet®</i>	50/500 mg, 50/850 mg & 50/1000 mg	Available	Available
Vildagliptin Tablets	Type 2 Diabetes Mellitus	Novartis	<i>Galvus®</i>	50 mg	Biowaiver	Available

PRODUCTS FOR OUTLICENSING

Products	Indication	Innovator Company	Innovator Brand	Strength & Dosage	BE Status	Dossier Status
Sitagliptin film-coated Tablets	Type 2 Diabetes Mellitus	Merck & Co. (MSD)	Januvia®	25 mg, 50 mg, 100 mg	Biowaiver	Available
Linezolid Tablets	Treating serious infections caused by multi-drug resistant Gram-positive bacteria, including MRSA and vancomycin-resistant Enterococcus faecium (VRE)	The Upjohn Co. (now part of Pfizer).	Zyvox	600 mg	Biowaiver	Available
Moxifloxacin Tablets	To treat bacterial infections like community-acquired pneumonia, acute sinusitis, complicated intra-abdominal infections, and bacterial conjunctivitis	Bayer AG	Avelox	400 mg	Biowaiver	Available
Varenicline Tablets	Smoking cessation used to help adults quit smoking by reducing nicotine cravings and withdrawal symptoms	Pfizer	Chantix (used in the US) and Champix (used internationally)	0.5 mg & 1.0 mg	Biowaiver	Available
Empagliflozin Tablets	SGLT2 inhibitor Type 2 Diabetes Mellitus; Heart Failure; Chronic Kidney Disease	Boehringer Ingelheim & Eli Lilly	Jardiance	10 mg & 25 mg	Pivotal BE planned in June 2026	Available
Dabigatran Etexilate Mesylate Capsules	To reduce the risk of stroke in patients with non-valvular atrial fibrillation and to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE)	Pradaxa	Pradaxa	75 mg, 110 mg & 150 mg	In pipeline	Available
Brivaracetam Tablets	Used for the treatment of partial-onset (focal) seizures in adults, adolescents, and pediatric patients 1 month of age & older	UCB Pharma	Briviact	10 mg, 25 mg, 50 mg, 75 mg & 100 mg	Biowaiver	Available
Sacubitril & Valsartan Tablets	Chronic Heart Failure	Novartis	Entresto	24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg	Available	Available
Dexlansoprazole DDR Capsules	GERD	Takeda Pharmaceutical Company Limited	Dexilant	30 mg & 60 mg	Pilot BE Completed	Available

Disclaimer: Products are subject to applicable patent rights/status in respective countries; commercialization shall commence only after patent expiry, lapse or lawful clearance, subject to applicable laws and approvals.

Invex Health Private Limited

Address: The Summit Business Bay (Omkar), Western Express Highway, Office No. 105, 1st Floor, Andheri - Kurla Rd, next to Guru Nanak Petrol Pump, Andheri East, Mumbai, Maharashtra 400093
www.invexhealth.com

Have a Product in Mind? Let's Unlock the Opportunity



Mr. Anudesh Goyal
Ms. Shivani Korgaonkar



anudesh@invexhealth.com
info@invexhealth.com



+91 7400476466
+91 9136169626

PRODUCTS FOR OUTLICENSING

Products	Innovator Company	Innovator Brand	Therapeutic Indication	Strength & Dosage	Regulatory Status
Bone Health					
Denosumab	Amgen Inc.	<i>Prolia®</i> , <i>Xgeva®</i>	Osteoporosis	60 mg & 120 mg	EUGMP Approved facility; Under Clinical Trial
Teriparatide	Eli Lilly	<i>Forteo (US)/ Forsteo (EU)</i>	Treatment of Severe osteoporosis	250 mcg/mL; pre-filled injector pen	EU Approval
Immunology					
Omalizumab	Genentech (Roche) & Novartis	<i>Xolair®</i>	Moderate-to-severe Allergic asthma; Chronic spontaneous urticaria	75, 150, 300 mg PFS / Autoinjector	MHRA approved; Filed in US, EU, Canada, Saudi Arabia
Abatacept	Bristol Myers Squibb	<i>Orencia®</i>	Rheumatoid Arthritis; psoriatic arthritis	125 mg/mL PFS/Al; 250 mg lyophilized IV	Ph-1 completed; US filing Q2/Q3 2027
Glatiramer acetate	Teva Pharmaceutical	<i>Copaxone®</i>	Relapsing multiple sclerosis	20mg/ml; 40mg/ml; Subcutaneous	USFDA Approved; ready for commercialization
Diabetes & Obesity					
Tirzepatide	Eli Lilly & Company	<i>Mounjaro®, Zepbound®</i>	Type 2 diabetes mellitus; chronic weight management	2.5/5/7.5/10/12.5/15 mg SC Inj	ANDA filed; USFDA-approved facility
Semaglutide Tablets	Novo Nordisk	<i>Rybelsus®</i>	Type 2 diabetes mellitus; weight management	R1 formulation: 3/7/14 mg; R2 formulation: 1.5/4/9 mg tablets	USFDA-approved facility
Semaglutide Inj / Vial	Novo Nordisk A/S	<i>Ozempic® / Wegovy®</i>	Type 2 diabetes mellitus; weight management	0.25/0.5/1/2 mg injection	ANDA filed; approval expected by 2026 end
Liraglutide	Novo Nordisk A/S	<i>Victoza®, Saxenda®</i>	Type 2 diabetes mellitus; weight management	6mg/ml (18mg/3ml Pen); SC injection	USFDA Approved & Commercialized
Anti-Infectives					
Ceftazidime + Avibactam	Pfizer	<i>Avycaz®, Zavicefta®</i>	Severe multidrug-resistant Gram-negative bacterial infections	2.5g/vial (2g/0.5g vial)	Facility Approved by EU-GMP (Hungary). Filed in various SEA countries
Liposomal Amphotericin B	Gilead Sciences	<i>Ambisome®</i>	Invasive systemic fungal infections	50mg/vial; lyophilized powder for Injection	Bioequivalence studies available Facility Approved by EU-GMP (Hungary) Filed in Canada, Turkey, SEA & African countries
Ceftriaxone + Sulbactam + EDTA	Venus Remedies	<i>Elores®</i>	Complicated MDR Gram-negative bacterial infections	Ceftriaxone 1000mg + Sulbactam 500mg + Disodium EDTA 37.5 mg; Inj	Dossier available for registration
Meropenem + Vaborbactam	Melinta Therapeutics	<i>Vabomere®</i>	Resistant Bacterial Infection	2g per vial	Under Pipeline. Please drop email for more information.
Oncology					
Carfilzomib	Amgen	<i>Kyprolis®</i>	Multiple myeloma	60 mg lyophilized powder	Dossier ready; EUGMP Approved facility
Pembrolizumab	Merck & Co., Inc.	<i>Keytruda®</i>	Multiple solid tumors	100mg/4ml (25mg/ml)	Under Clinical Trial Stage
Nivolumab	Bristol Myers Squibb	<i>Opdivo®</i>	Advanced, metastatic or unresectable NSCLC, lung cancer	40mg/4ml; 100mg/10ml; 240mg/24ml; prefilled syringe	Under Clinical Trial Stage
Pertuzumab	Genentech / Roche	<i>Perjeta®</i>	Breast cancer	420mg/14ml IV	Under Clinical Trial Stage
Fulvestrant	AstraZeneca	<i>Faslodex®</i>	Advanced metastatic breast cancer	250mg PFS	Dossier ready; EUGMP Approved facility
Azacitidine	Celgene / BMS	<i>Vidaza®, Onureg®</i>	Acute myeloid leukemia	100mg/vial; 200, 300mg tablets	Dossier ready; EUGMP Approved facility
Peg Asparaginase	Enzon Pharmaceuticals	<i>Oncaspar®</i>	Acute lymphoblastic leukemia	3,750 IU/5ml (750 IU/ml) IV/IM	Dossier ready; EUGMP Approved facility
Nab-Paclitaxel	Abraxis BioScience (later Celgene – Bristol Myers Squibb)	<i>Abraxane®</i>	Breast, lung, pancreatic cancer	100mg/vial	Dossier ready; EUGMP Approved facility
Enzalutamide	Medivation Inc. (co-developed with Astellas Pharma)	<i>Xtandi®</i>	Prostate cancer	Soft gel cap - 40mg; Film-coated tablets - 40, 80mg	Under Registration in EU

PRODUCTS FOR OUTLICENSING

Products	Innovator Company	Innovator Brand	Therapeutic Indication	Strength & Dosage	Regulatory Status
Oncology					
Abiraterone	Cougar Biotechnology, Inc. (acquired by J&J)	Zytiga®	Prostate cancer	250, 500mg Film-coated tablets	Dossier ready
Nilotinib	Novartis AG	Tasigna®	Chronic myeloid leukemia	Capsules 150 & 200 MG mg	Dossier ready
Pazopanib	GLaxoSmithKline	Votrient®	Kidney; soft tissue cancer	200, 400mg Film-coated tablets	Dossier ready
Ibrutinib	Pharmacyclics (AbbVie) / Janssen	Imbruvica®	Blood cancer	Capsules 70, 140mg	Dossier ready
Olaparib	AstraZeneca	Lynparza®	BRCA-related cancers	100, 150mg Film-coated tablets	Dossier ready
Daratumumab	Genmab	Darzalex®	Multiple myeloma	100mg/5ml; 400mg/20ml	Under Pipeline. Please drop email for more information.
Durvalumab	AstraZeneca	Imfinzi®	Lung cancer; Biliary tract cancer	120mg/2.4ml; 500mg/10ml	Under Pipeline. Please drop email for more information.
Palbociclib	Pfizer	Ibrance®	HR+/HER2- breast cancer	Tablets/Capsules - 75, 100, 125mg	Under Pipeline. Please drop email for more information.
Acalabrutinib	Medivation / Astellas Pharma; acquired by Pfizer	Calquence®	Prostate cancer	Capsules - 40mg; Tablets - 40, 80mg	Under Pipeline. Please drop email for more information.
Respiratory					
Nintedanib	Boehringer Ingelheim	Ofev®	Pulmonary Fibrosis & lung disease	100, 150 mg capsules	USFDA Approved
Endocrinology					
Lanreotide	Ipsen	Somatuline Depot® / Autogel®	Acromegaly, neuroendocrine tumors	60, 90, 120 mg prolonged-release solution; pre-filled syringe	US & EU filed
Reproductive Health					
Goserelin	AstraZeneca	Zoladex®	Prostate cancer; Endometriosis; Endometrial thinning; Uterine fibroids	3.6mg, 10.8mg	Under Pipeline. Please drop email for more information.
Leuprolide	AbbVie	Lupron Depot®	Prostate cancer; Endometriosis; Uterine fibroids	1, 3.75, 7.5, 11.25, 22.5, 30, 45 mg injection	Under Clinical Trials
Ophthalmology					
Aflibercept	Regeneron / Bayer	Eylea®	Age-related macular degeneration & various retinal diseases	2mg/0.05ml injection	Under Pipeline. Please drop email for more information.
Cardiovascular					
Tafamidis	Pfizer	Vyndaqel® / Vyndamax®	Treatment of transthyretin amyloidosis	61 mg & 20 mg capsules	USFDA Approved
Apixaban	BMS / Pfizer	Eliquis®	Anticoagulant	2.5, 5mg Film-coated tablets	Dossier ready; BE available
Edoxaban	Daiichi Sankyo	Savaysa®	Atrial fibrillation, DVT, PE	15, 30, 60mg tablets	Under Pipeline. Please drop email for more information.
Inclisiran	Novartis	Leqvio®	Hypercholesterolemia	284mg/1.5ml single-dose PFS	Under Pipeline. Please drop email for more information.
Selexipag	Actelion (now J&J Innovative Medicine)	Uptravi®	Pulmonary arterial hypertension	Tablets & Injection	Under Pipeline. Please drop email for more information.

Disclaimer: Products are subject to applicable patent rights/status in respective countries; commercialization shall commence only after patent expiry, lapse or lawful clearance, subject to applicable laws and approvals.

Invex Health Private Limited

Address: The Summit Business Bay (Omkar), Western Express Highway, Office No. 105, 1st Floor, Andheri - Kurla Rd, next to Guru Nanak Petrol Pump, Andheri East, Mumbai, Maharashtra 400093

www.invexhealth.com

Have a Product in Mind? Let's Unlock the Opportunity



Mr. Anudesh Goyal
Ms. Shivani Korgaonkar



anudesh@invexhealth.com
info@invexhealth.com



+91 7400476466
+91 9136169626